Table 2 Scenarios 1-6 in the simulation study. Doses with dose limiting toxicities in the targeted toxicity interval (0.20 - 0.40) are in boldface. Scenarios 1-6 represent phase I trials with one schedule, that is daily schedule
From: Phase I dose-escalation oncology trials with sequential multiple schedules
| Doses in mg | ||||||
|---|---|---|---|---|---|---|
| Scenario | 2.5 | 5 | 7.5 | 10 | 12.5 | 15 |
| 1 | 0.05 | 0.10 | 0.20 | 0.30 | 0.50 | 0.70 |
| 2 | 0.30 | 0.40 | 0.52 | 0.61 | 0.76 | 0.87 |
| 3 | 0.05 | 0.06 | 0.08 | 0.11 | 0.19 | 0.34 |
| 4 | 0.06 | 0.08 | 0.12 | 0.18 | 0.40 | 0.71 |
| 5 | 0.10 | 0.22 | 0.31 | 0.45 | 0.60 | 0.72 |
| 6 | 0.50 | 0.55 | 0.61 | 0.69 | 0.76 | 0.87 |